Search tool

Commissioned each year by the EMCDDA and produced by the national focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level in...

Summary: Commissioned each year by the EMCDDA and produced by the national focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level...

Commissioned each year by the EMCDDA and produced by the national focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level in...

Commissioned each year by the EMCDDA and produced by the national focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level in...

Cannabis is the illegal substance most commonly used in all countries of the European Union. The increased use of cannabis during the past decade has increased the profile of the drug. Used...

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. The newsletter aims to offer a complete overview of the work of the Agency and...

Prevalence of problem drug use (PDU) is one of five key indicators used by the EMCDDA to provide more comparable, scientifically based estimates of the prevalence of more severe patterns of drug...

The risk-assessment reports on the synthetic drugs 2C-I; 2C-T-2 and 2C-T-7 were submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The reports were drawn up at...

The risk-assessment report on the synthetic drug TMA-2 was submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The report was drawn up at a meeting in...

The General report of activities is an annual publication providing a detailed progress report of the EMCDDA's activities over a 12-month period. Published every spring, it catalogues the Centre's achievements in each...